- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
New Open MRI System from Fujifilm Combines Technology Advances with Patient Comfort
The Aperto Lucent open 0.4T MRI platform reportedly offers enhanced fat suppression and spatial resolution capabilities in addition to its open architecture design.
Emphasizing patient comfort, workflow efficiencies and enhanced imaging quality, Fujifilm has launched the Aperto Lucent open 0.4T magnetic resonance imaging (MRI) system.
The system’s wide laterally moving table and single-pillar design are key factors in promoting patient comfort, according to Fujifilm.
In addition to the platform’s permanent magnet technology, the company said the Aperto Lucent provides an array of features to facilitate efficient quality imaging.
In addition to promoting patient comfort, the Aperto Lucent open 0.4T MRI system reportedly provides enhanced fat suppression capabilities and improved spatial resolution. (Image courtesy of Fujifilm.)
• Fat suppression features include eight channels of active patient shimming and chemical shift-selective (CHESS) type radiofrequency (RF) fat saturation, which complements short tau inversion recovery (STIR) sequences.
• A combination of solenoid technology RF receiver coils and the IP-Recon iterative image reconstruction algorithm facilitate a high signal-to-noise ratio (SNR) and enhanced spatial resolution, according to Fujifilm.
• In order to address challenges with patient motion, Fujifilm said the Aperto Lucent system has RADAR motion compensating pulse sequence technology that reduces artifacts and the potential for rescans.
“APERTO Lucent is a perfect solution for providers looking for a space-saving, cost-effective system that enhances the MRI patient experience,” noted Shawn Etheridge, the executive director of modality solutions marketing for Fujifilm Healthcare Americas Corporation. “With permanent magnet open MRI technology, there is little need for additional equipment and infrastructure to maintain the magnetic field, keeping installation and operating costs low for our customers and providing a stronger return on investment.”
Diffusion-Weighted MRI and Neoadjuvant Chemotherapy for Rectal Cancer: What New Research Reveals
September 3rd 2024In a comparison of imaging assessments to gauge the effectiveness of neoadjuvant chemotherapy for rectal adenocarcinoma, researchers found the combination of diffusion-weighted imaging and MR tumor regression grading had a 90 percent area under the curve (AUC) and a negative predictive value (NPV) of 93 percent.
New Research Highlights Emerging MRI Contrast Agent for Bladder Imaging
August 21st 2024A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
MRI Study Offers Insights on Traumatic Brain Injury and Cerebral Microbleeds
August 19th 2024Detecting cerebral microbleed (CMB) in one of six healthy adults in a new study, researchers also found that CMB was the only MRI marker of small vessel disease (SVD) to be significantly associated with traumatic brain injury (TBI).
